<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 06 Jun 2021 07:31:00 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>GPCR抗体药物的研发进展</title><link>https://mp.weixin.qq.com/s/HJbEqivB-k6JSe8CYbENeg</link><description></description><content:encoded><![CDATA[GPCR抗体药物的研发进展]]></content:encoded><pubDate>Sun, 06 Jun 2021 06:34:27 +0800</pubDate></item><item><title>靶向GPCR受体复合物：药物发现的新方向</title><link>https://mp.weixin.qq.com/s/PDcWyLjn79jc6S3E1lsPzg</link><description></description><content:encoded><![CDATA[靶向GPCR受体复合物：药物发现的新方向]]></content:encoded><pubDate>Sun, 06 Jun 2021 06:34:27 +0800</pubDate></item><item><title>GPCR的偏向配体</title><link>https://mp.weixin.qq.com/s/O5-rREHeB_ji5u7qm_r_Bw</link><description></description><content:encoded><![CDATA[GPCR的偏向配体]]></content:encoded><pubDate>Sun, 06 Jun 2021 06:34:27 +0800</pubDate></item><item><title>GPCR药物靶点的自然遗传变异</title><link>https://mp.weixin.qq.com/s/K70laQatAuOCc6LkcY15cA</link><description></description><content:encoded><![CDATA[GPCR药物靶点的自然遗传变异]]></content:encoded><pubDate>Sun, 06 Jun 2021 06:34:27 +0800</pubDate></item><item><title>奥氮平复方制剂Lybalvi获FDA批准上市，可降低奥氮平导致的体重增加</title><link>https://mp.weixin.qq.com/s/_-qLYMgKcIjg_3T1vr5t4w</link><description></description><content:encoded><![CDATA[奥氮平复方制剂Lybalvi获FDA批准上市，可降低奥氮平导致的体重增加]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:43:23 +0800</pubDate></item><item><title>肿瘤免疫明星靶点之CD137：双抗及Combo策略</title><link>https://mp.weixin.qq.com/s/nVUBI3KspEHNi6TmXI4eEQ</link><description></description><content:encoded><![CDATA[肿瘤免疫明星靶点之CD137：双抗及Combo策略]]></content:encoded><pubDate>Fri, 04 Jun 2021 06:30:30 +0800</pubDate></item><item><title>喜报｜博际生物医药PD-L1/TGFβ双功能性融合蛋白获美国FDA批准进入临床试验</title><link>https://mp.weixin.qq.com/s/EgcGjy8qcFZHOhxZ-8bG0A</link><description></description><content:encoded><![CDATA[喜报｜博际生物医药PD-L1/TGFβ双功能性融合蛋白获美国FDA批准进入临床试验]]></content:encoded><pubDate>Fri, 04 Jun 2021 06:30:30 +0800</pubDate></item><item><title>邀请函|9月第6届广州国际生物技术大会暨展览会</title><link>https://mp.weixin.qq.com/s/8B8LEH56hIVJC4BE5pb7rg</link><description></description><content:encoded><![CDATA[邀请函|9月第6届广州国际生物技术大会暨展览会]]></content:encoded><pubDate>Fri, 04 Jun 2021 06:30:30 +0800</pubDate></item><item><title>2020全球新药研发回顾</title><link>https://mp.weixin.qq.com/s/7jFaiizZG1UYqUD_NQnNEA</link><description></description><content:encoded><![CDATA[2020全球新药研发回顾]]></content:encoded><pubDate>Thu, 03 Jun 2021 06:18:10 +0800</pubDate></item><item><title>CAR-T治疗中的细胞因子释放综合征与相关神经毒性</title><link>https://mp.weixin.qq.com/s/ca6KlNUOQjxC_n-2DV5w6w</link><description></description><content:encoded><![CDATA[CAR-T治疗中的细胞因子释放综合征与相关神经毒性]]></content:encoded><pubDate>Wed, 02 Jun 2021 07:20:07 +0800</pubDate></item><item><title>新药论坛三箭齐发，吐槽大会爆笑江湖｜BiG年会DAY 2</title><link>https://mp.weixin.qq.com/s/fzvAiPl0WIQZAbmBLtVNXw</link><description></description><content:encoded><![CDATA[新药论坛三箭齐发，吐槽大会爆笑江湖｜BiG年会DAY 2]]></content:encoded><pubDate>Wed, 02 Jun 2021 07:20:07 +0800</pubDate></item><item><title>双特异性抗体的发展历程！</title><link>https://mp.weixin.qq.com/s/UkHdxlBocWvDeI9DDh8hdA</link><description></description><content:encoded><![CDATA[双特异性抗体的发展历程！]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>SIRPa抗体单药实体瘤安全有效，力压CD47，大有可为</title><link>https://mp.weixin.qq.com/s/TN2n3ztWW5cPuAtTyNC-lg</link><description></description><content:encoded><![CDATA[SIRPa抗体单药实体瘤安全有效，力压CD47，大有可为]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>双抗、ADC新玩家入局，5月融资企业“挑战”龙头地位</title><link>https://mp.weixin.qq.com/s/zZvc-mKf3q7drRPEUWvmVA</link><description></description><content:encoded><![CDATA[双抗、ADC新玩家入局，5月融资企业“挑战”龙头地位]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>免疫学拾遗-第14章：B细胞的发育</title><link>https://mp.weixin.qq.com/s/s5Ya54K5a0KcbJWPmL3Vpg</link><description></description><content:encoded><![CDATA[免疫学拾遗-第14章：B细胞的发育]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>免疫学拾遗-第15章：T细胞的发育</title><link>https://mp.weixin.qq.com/s/Y-R8jhdVUoR_gZQZ4NTkCw</link><description></description><content:encoded><![CDATA[免疫学拾遗-第15章：T细胞的发育]]></content:encoded><pubDate>Tue, 01 Jun 2021 06:47:19 +0800</pubDate></item><item><title>张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况</title><link>https://mp.weixin.qq.com/s/Mmw3NhDGQg-bVJcKEo5J5w</link><description></description><content:encoded><![CDATA[张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况]]></content:encoded><pubDate>Mon, 31 May 2021 06:52:46 +0800</pubDate></item><item><title>IL7融合蛋白临床疗效初现</title><link>https://mp.weixin.qq.com/s/P8yNccGdy_SNNkKGVvDUGA</link><description></description><content:encoded><![CDATA[IL7融合蛋白临床疗效初现]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>盘点2021上市的抗体新药-（4）amivantamab-vmjw</title><link>https://mp.weixin.qq.com/s/nP8q8iWAJSXAC2L2SwxLmQ</link><description></description><content:encoded><![CDATA[盘点2021上市的抗体新药-（4）amivantamab-vmjw]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路</title><link>https://mp.weixin.qq.com/s/4FAhtzkS_EFdIZVFmDpdLA</link><description></description><content:encoded><![CDATA[重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路]]></content:encoded><pubDate>Sat, 29 May 2021 07:20:49 +0800</pubDate></item></channel></rss>